Compounds > ethyldeshydroxysparsomycin
Page last updated: 2024-12-11

ethyldeshydroxysparsomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethyldeshydroxysparsomycin: structure given in first source; RN for (R-(R*,S*-(E)))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436444
MeSH IDM0200154

Synonyms (7)

Synonym
ethyldeshydroxysparsomycin
(e)-n-[1-(ethylsulfanylmethylsulfinyl)propan-2-yl]-3-(6-methyl-2,4-dioxo-1h-pyrimidin-5-yl)prop-2-enamide
2-propenamide, n-(2-(((ethylthio)methyl)sulfinyl)-1-methylethyl)-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-, (r-(r*,s*-(e)))-
edsm
ethyldeshydroxy-sparsomycin
119410-38-7
DTXSID80874605

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Possible long-range retinotoxic effects of EdSm were investigated in tumour-bearing mice, cured after surviving treatment with LD50 doses of EdSm, by assaying the protein biosynthetic capacity of the retinal by assaying the ocular rhodopsin and opsin levels as parameters."( Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Bovee, PH; De Grip, WJ; De Vos, D; Hofs, HP; Ottenheijm, HC; Wagener, DJ; Winkens, HJ, 1995)		0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
"The efficacy of cisplatin (CDDP) in combination with the protein synthesis inhibitor ethyldeshydroxysparsomycin (EDSM) has been tested in two tumor models at various schedules."( Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.
De Grip, WJ; De Valk-Bakker, V; De Vos, D; Doesburg, WH; Hofs, HP; Ottenheijm, HC; Van Rennes, H; Wagener, DJ, 1995)		0.79
" Our results show that in the B16 tumor model EDSM is not able to potentiate any of these drugs, whereas antagonism is seen in combination with doxo-rubicin (DX)."( Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents.
de Grip, WJ; de Valk-Bakker, V; de Vos, D; Doesburg, WH; Hofs, HP; Ottenheijm, HC; van Rennes, H; Wagener, DJ, 1995)		0.29
" When drug ratios were used, synergism was observed upon pre- and post-treatment in combination with cisplatin, cytosine arabinoside (Ara-C), methotrexate (MTX) and 5-fluorouracil (5-FU)."( Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents.
de Grip, WJ; de Valk-Bakker, V; Hofs, HP; Ottenheijm, HC; van Rennes, H; Wagener, DJ, 1994)		0.29

Dosage Studied

ExcerptRelevanceReference
" EdSm showed a clear dose-response effect in vitro."( Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Bovee, PH; De Grip, WJ; De Vos, D; Hofs, HP; Ottenheijm, HC; Wagener, DJ; Winkens, HJ, 1995)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		1.98101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		1.9810organic bromide saltcolorimetric reagent;
dye
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		1.9910glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
sparsomycin
Sparsomycin: An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems.		3.2460
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.940
B16 Melanoma
[description not available]		02.6830
Benign Neoplasms
[description not available]		01.9810
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9810